Comparing a “See-and-Treat” HPV-Based to VIA-Based Cervical Cancer Prevention Strategies Among Women Living with HIV in Cameroon: A Pilot Study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background Women living with HIV (WLWH) have a higher vulnerability to developing cervical cancer and should be prioritized for screening. The objective of this study was to test the feasibility of integrating HPV-based vis-à-vis VIA-based cervical cancer prevention services into routine HIV Care and Treatment in Cameroon. Methods We conducted a comparative cross-sectional study of two groups of WLWH aged 25 years and above; a group screened with Human Papillomavirus (HPV) DNA (HPV Group) and a group screened with Visual Inspection with Acetic Acid (VIA) (VIA Group), using the see-and-treat approach. The proportion of treatment-eligible women who received treatment per screening approach was calculated. Results A total of 325 WLWH were screened as follows; VIA Group, N = 184 (45.5%) and HPV Group, N = 177 (54.5%). Among these 325 women, 74 (22.8%) were positive for either HPV and/or VIA. Of these 74, 64 (86.5%) were of the HPV Group and 10 (13.5%) were of the VIA Group. Among the 74 positive women, 14 (18.9%) received treatment. Among the 36.2% treatment-eligible women in the HPV Group, 5/64 (9.4%) had VIA-positive lesions. Among the 10 women in the VIA Group who tested positive for VIA, only 1 (10%) received treatment. Whereas, among the 5 women with VIA-positive lesions in the HPV Group, 4 (80%) received treatment. Conclusion The treatment uptake was low (18.9%). Performing screening without treating the treatment-eligible cases will not create any reduction in cervical cancer morbidity/mortality. Therefore, more strategies are needed to enable WLWH who screen positive for HPV/VIA get adequate treatment.

Article activity feed